Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.46 |
| ▸ | TUBB | P07437 | 3/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4991334 | 1.00 | POLB (0.60) | POLBALDH1A1MAPTCYP3A4SMN1; SMN2 | |
| SCHEMBL5194113 | 0.84 | CYP1A2 (0.52) | MAPTCYP3A4SMN1; SMN2RECQLHIF1A | |
| SCHEMBL5191609 | 0.81 | PDE4A (0.57) | ALDH1A1MAPT | |
| SCHEMBL4998844 | 0.81 | TUBB4A (0.57) | SMN1; SMN2RECQLHIF1AEGFRPDGFRB | |
| SCHEMBL4998847 | 0.81 | TUBB4A (0.57) | SMN1; SMN2RECQLHIF1AEGFRPDGFRB | |
| SCHEMBL4821938 | 0.80 | PDE4A (0.59) | MAPTSMN1; SMN2RECQLHIF1AEGFR | |
| SCHEMBL8397000 | 0.80 | HIF1A (0.56) | CYP3A4SMN1; SMN2RECQLHIF1AEGFR | |
| SCHEMBL4821934 | 0.80 | PDE4A (0.59) | MAPTSMN1; SMN2RECQLHIF1AEGFR | |
| SCHEMBL8397001 | 0.80 | HIF1A (0.56) | CYP3A4SMN1; SMN2RECQLHIF1AEGFR | |
| SCHEMBL5190968 | 0.80 | PDE4A (0.50) | ALDH1A1MAPTCYP3A4TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371773-B2 | Breast cancer resistance protein (BCRP) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-13 | — | — | US | claimed |
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-15 | — | — | US | claimed |
| EP-1591117-A1 | BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2005-11-02 | — | — | EP | claimed |
| US-7371773-B2 | Breast cancer resistance protein (BCRP) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591117-A1 | BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | ABCC1, OSBP, OSBPL3 | POLB 4081/4885ALDH1A1 1336/4885MAPT 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.